Indoco Remedies Share Price

Indoco Remedies Limited, incorporated on August 23, 1947 is a Mumbaibased pharmaceutical company focused on formulations, with some presence in contract manufacturing and research. The Company headquartered in Mumbai, is a fully integrated, researchoriented pharma Company with presence in 55 countries. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 212 million company has 11 manufacturing facilities, 7 of which are for FDFs and 4 for APIs, supported by a stateoftheart RD Centre and a CRO facility.Currently, Indoco has a presence in therapeutic segments including antiinfective, anticold preparation, opthalmic, antispasmodic, stomatology, antiinflammatory and antifungal. As per AC Nielsen ORGMARG market survey (August 2004) of doctors, Indoco ranked first in the stomatology, ninth in the opthalmic and twelve in the pediatric segments in terms of prescription generation in the domestic market. In the overall pharma industry, Indoco is ranked 34th as per AC Nielsen ORGMARG Retail Audit, but ranked 23rd in terms of prescription generation, indicating the strength of its marketing network. Further, the company last year launched a new super specialty division, with focus on diabetic and cardiovascular segments. Its entry into the lifestyle segment with a strong presence in the prescription segment would augur well for the higher thanaverage industry growth. Currently, Indoco has 4 manufacturing facilities. Two are located in Mumbai and two in Goa, and an RD centre in Mumbai. The solid dosage facility in Goa has been accredited by UKMedicines and Healthcare Products Regulatory Agency (MHRA), and the sterile plant of Goa has been designed as per US Food and Drug Administration (FDA) norms. On the selling front, it has a marketing network of 1,248 medical representatives.In July 2014, the Company purchased the remaining shares of its subsidiary, Xtend Industrial Designers and Engineers Private Limited to make it a 100% subsidiary of the Company.In April 2015, the Company acquired from Piramal Enterprise Limited, their Clinical Research Division, located in Hyderabad. The division is equipped with a 98bed facility, including a fourbed ICU, stateoftheart analytical lab and capabilities of eCTD submission. It also has GCP certification from UKMHRA and also has regulatory approvals from several bodies including USFDA. The acquisition would reduce the Companys dependability to outsource bioequivalence studies. This will not only reduce cost but also ensure timebound outcome of studies and add pace to the Companys existing RD efforts.In December, 2015, the Company incorporated Indoco Remedies Singapore Pte Limited, a 100% subsidiary. The subsidiary will be used for the expansion of the companys ambitious plans to extend its activities in the European and US markets. The company has the following 3 subsidiary companies as on 31 March 2016.i. Xtend Industrial Designers and Engineers Private Limited,ii. Indoco Pharmchem Limited,iii. Indoco Remedies Singapore Pte. Ltd.During the year 201718, the Company (FD) was granted two patents by the Indian Patent Office and one by United States Patents Office for formulation of Olopatadine, Gliclazide, and Brinzolamide respectively. The Company was also granted three patents by Indian Patents Office for manufacturing processes of three APIs, viz., Febuxostat, Rufinamide and Lacosamide.Indocos RD efforts received due recognition with the Best Process Patent Award for the year 20162017 forfive Indian patents granted related to Processforthe preparation of Tapentadol, Process for the preparation of Aminoindane compound, Process for preparation of Pyrazole derivatives, Preparation of phenylacetic acid derivative and Preparation of Substituted 1Himidazo4,5c quinoline. This award was presented at Indian Drug Manufacturers Associations 56th Annual Day celebrations held on 20 January 2018.100% subsidiary known as Indoco Remedies Singapore Pte Ltd. was set up in the Czech Republic effective from April 9, 2019.In August21, Company received GCP GLP Accreditation from the UKMHRA (Medicines and Healthcare Products Regulatory Agency) for its Clinical Research Division AnaCipher, located at Hyderabad. The Company launched six new products (SKUs), two in the acute segment, Naricover and Dropizin Syrup, one in the chronic segment, Methycal 60 K and three in the subchronic segment, Rexidin SRS, Noxa and Subitral in the domestic market in 2022. In 2023, Company acquired 85% equity stake in the US based FPP Holding Company, LLC for USD 4 million from Contract Pharmacal Corp. (CPC). Warren Remedies Private Limited a wholly owned subsidiary of the Company, was incorporated in 202223 for setting up a unit for manufacturing of pharmaceutical products both formulations as well as Active Pharmaceutical Ingredients (API). The Company acquired 26% equity stake each in Kanakal Wind Energy Private Limited and Jalansar Wind Energy Private Limited, representing 8,64,000 equity shares of Rs 10/ each and 5,76,000 equity shares of Rs 10/ each respectively, for setting up Solar Power Plant at Akkalkot, Solapur District, Maharashtra.

Indoco Remedies reported a Q1 FY 2025-26 revenue of ₹437.89 crore, down -8.6% YoY, with net profit decreased -180.4% to ₹-36.35 crore. For the full year FY2025–2026, revenue reached ₹1670.37 crore and profit touched at ₹-77.95 crore. As of Jun '25, Indoco Remedies’s market capitalisation stood at ₹2,687.64 crores. Shareholding as of Jun '25 shows promoters holding 58.9%, with FIIs at 1.2%, DIIs at 19%, and public at 20.8%.

As of 20 Aug, 2025, Indoco Remedies share price is ₹287.2. The stock opened at ₹291 and had closed at ₹291.4 the previous day. During today’s trading session, Indoco Remedies share price moved between ₹286.95 and ₹291.00, with an average price for the day of ₹288.98. Over the last 52 weeks, the stock has recorded a low of ₹190.00 and a high of ₹387.55. In terms of performance, Indoco Remedies share price has increased by 19.4% over the past six months and has declined by 12.61% over the last year.